In this scenario, regorafenib is an oral multikinase inhibitor that targets different protein kinases involved in key oncogenic pathways, such as angiogenesis by blocking vascular endothelial growth factor receptor-1 (VEGFR-1), 2 and 3 and tyrosine kinases, immunoglobulin and epidermal growth factor (EGF) homology domain 2 (TIE-2) tyrosine kinase; such as tumor progression by inhibition KIT, RET, RAF-1 and BRAF; and such as tumor microenvironment by blocking platelet derived growth factor receptor-β (PDGR-β) and fibroblast growth factor receptor (FGFR) tyrosine kinases [3–4]. The gene discussed is BRAF; the disease is neoplasm.